Published in AIDS Weekly and Law, June 8th, 2006
"Resistance analyses were performed on a Bristol-Myers Squibb-sponsored study comparing the safety and efficacy of atazanavir/ritonavir to lopinavir/ritonavir in treatment-experienced subjects at 48 weeks," explained Lisa K. Naeger and Kimberly A. Struble at the U.S. Food and Drug Administration. "Analyses evaluated virologic response based on the presence of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.